XOMA Virtual Fireside Chat with H.C. Wainwright & Co.
Virtual, July 20, 2021
Join XOMA Corporation for a virtual fireside chat with Joseph Pantginis, Ph.D, of H.C. Wainwright & Co., discussing the royalty aggregator model and what’s next for XOMA. XOMA monetizes and aggregates royalty payment rights associated with pre-commercial drug candidates with a focus on development-stage assets with blockbuster potential that are licensed to well-capitalized partners. They use a portfolio approach to acquire new assets, thereby mitigating single-asset binary exposure.
Joseph Pantginis, Ph.D., H.C Wainwright & Co., Managing Director of Equity Research
James Neal, XOMA, Chief Executive Officer and member of the Board
Thomas Burns, XOMA, Senior Vice President, Finance and Chief Financial Officer
XOMA Corporation [XOMA] $206 MM MCap
Biotech royalty and milestone aggregator with portfolio of 70+ assets in >30 disclosed indications where R&D costs are borne by partners e.g. Roche's Faricimab (BLA filed for nAMD and DME 7/29/21) [more information]